Okada, Hiroshi
Tanaka, Muhei
Yasuda, Takashi
Kamitani, Tadaaki
Norikae, Hisahiro
Fujita, Tetsuya
Nishi, Takashi
Oyamada, Hirokazu
Yamane, Tetsuro
Fukui, Michiaki
Article History
Received: 28 May 2018
Accepted: 28 September 2018
First Online: 3 October 2018
Compliance with ethical standards
:
: Michiaki Fukui received grants from the Japan Society for the Promotion of Science, AstraZeneca Plc, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. The sponsors were not involved in the study design; the collection, analysis, and interpretation of data; the writing of this manuscript; or the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by a pharmaceutical company, the authors received no current funding for this study, and this does not alter their adherence to all the journal policies on sharing data and materials. The other authors have no conflict of interest to disclose.